Peritoneal Carcinomatosis: Drugs and Diseases

  • Paul H. Sugarbaker

Part of the Cancer Treatment and Research book series (CTAR, volume 81)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Pharmacology

    1. Maurie Markman
      Pages 1-5
    2. Arvil D. Stephens, James F. Belliveau, Paul H. Sugarbaker
      Pages 15-30
    3. Karl H. Link, G. Hepp, L. Staib, U. Butzer, W. Böhm, H. G. Beger
      Pages 31-40
    4. Vicente Fernández-Trigo, O. Anthony Stuart, Arvil D. Stephens, Louis D. Hoover, Paul H. Sugarbaker
      Pages 51-61
  3. Disease States

    1. Tessa A. Sugarbaker, David Chang, Patricia Koslowe, Paul H. Sugarbaker
      Pages 63-74
    2. Paul H. Sugarbaker
      Pages 105-119
    3. Paul H. Sugarbaker, Vicente Fernández-Trigo, Falah Shamsa
      Pages 121-132
    4. Shigeru Fujimoto, Makoto Takahashi, Takaaki Mutou, Kokuriki Kobayashi, Tadashi Toyosawa, Kimikazu Kondoh et al.
      Pages 169-176
    5. Toshio Takahashi, Masataka Shimotsuma, Akeo Hagiwara, Toshiharu Yamaguchi
      Pages 185-192
    6. Andrew M. Averbach, Paul H. Sugarbaker
      Pages 193-211
    7. Mary E. Kass
      Pages 213-225
    8. Stephen E. Ettinghausen, Andrew M. Averbach
      Pages 227-237
    9. Shigeru Fujimoto, Makoto Takahashi, Kokuriki Kobayashi, Junji Kasanuki, Haruo Ohkubo
      Pages 239-245
    10. Monique E. T. Schellinx, Maarten F. von Meyenfeldt, Paul H. Sugarbaker
      Pages 247-260
  4. Back Matter
    Pages 261-269

About this book


Peritoneal carcinomatosis dominates the clinical picture of many patients with gastrointestinal, gynecological and urological cancers. For many of them its dev­ astating effects contribute directly to their death. Most clinicians consider peritoneal carcinomatosis an incurable metastatic disease and give palliative treatment, re­ stricted to limited surgery and systemic chemotherapy. Contrary to this view, Paul Sugarbaker and his collegues base their approach on the concept that peritoneal carcinomatosis represents regional tumor spread, similar in its impact on treatment and prognosis to that of lymph node metastases in other malignancies. This concept emphasises the value of regional tumor control, as a potentially curative measure. In this book the combination of aggressive cytoreduction and intraperitoneal chemotherapy to control peritoneal carcinomatosis is extensively explored. Basic to this approach is the observation that most cancer cells show only relative resistence against commonly available drugs, which can be overcome by a sufficient increase of drug concentrations in tumor tissue. After intraperitoneal delivery, drugs will reach high tissue concentrations in the superficial few cell layers, while plasma concentrations will remain below toxic levels. Patients with only limited residual tumor at the peritoneal surface after cytoreduction may therefore benefit from intraperitoneal chemotherapy.


carcinoma gastric cancer immunotherapy mesothelioma metastasis pathology pharmacology prevention surgery tumor

Editors and affiliations

  • Paul H. Sugarbaker
    • 1
  1. 1.Washington Cancer InstituteWashington Hospital CenterUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag US 1996
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-0-7923-3726-3
  • Online ISBN 978-1-4613-1245-1
  • Series Print ISSN 0927-3042
  • Buy this book on publisher's site